dalteparin and Dizzyness studies

dalteparin and Dizzyness

dalteparin has been researched along with Dizzyness in 1 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Research Excerpts

Excerpt	Relevance	Reference
" SC weight-based dosing on off-dialysis days is a feasible regimen for further clinical thromboprophylaxis efficacy studies in hemodialysis patients."	2.70	Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ( Assaid, CA; Barrett, JS; Cox, DS; Fossler, MJ; Hainer, JW; Hua, TA; Pittenger, AL; Sherrard, DJ; Stephenson, CA; Swan, SK; Williams, RM, 2002)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

1 (100.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Hainer, JW	1
Sherrard, DJ	1
Swan, SK	1
Barrett, JS	1
Assaid, CA	1
Fossler, MJ	1
Cox, DS	1
Williams, RM	1
Pittenger, AL	1
Stephenson, CA	1
Hua, TA	1

Studies

Hainer, JW

Sherrard, DJ

Swan, SK

Barrett, JS

Assaid, CA

Fossler, MJ

Cox, DS

Williams, RM

Pittenger, AL

Stephenson, CA

Hua, TA

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418]		28 participants (Actual)	Observational	2016-02-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418]

28 participants (Actual)

Observational

2016-02-01

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for dalteparin and Dizzyness

Article	Year
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:3 Topics: Adolescent; Adult; Aged; Antithrombin III; Biomarkers; Blood Coagulation; Cross-Over Studies; Dizzin	2002

Article

Year

Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:3

Topics: Adolescent; Adult; Aged; Antithrombin III; Biomarkers; Blood Coagulation; Cross-Over Studies; Dizzin

2002